8-K - Oramed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Oramed Pharmaceuticals Inc. completed the sale of its subsidiary Oratech Pharma, Inc. to Lifeward Ltd. and concurrently invested $9 million in Lifeward through convertible notes, receiving equity and warrants in both transactions.

Key Takeaways

1Oramed sold its wholly-owned subsidiary Oratech to Lifeward, receiving Lifeward ordinary shares, pre-funded warrants, and share purchase warrants as consideration.

2The transaction includes ongoing revenue-sharing payments equal to 4% of net revenue from Lifeward's ReWalk Personal Exoskeleton products for up to 10 years or until certain conditions are met.

3Concurrently, Oramed purchased $9 million in senior secured convertible notes from Lifeward, receiving additional warrants to purchase Lifeward ordinary shares.

4Both the acquisition of Oratech and the private placement of notes closed on March 25, 2026, finalizing the previously announced agreements.

Current Report Details

Event Type

Material Agreement

Asset Acquisition

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry Into a Material Definitive Agreement.** Closing of Share Purchase Agreement As previously reported in a Current Report on Form 8-K filed with the Securi

Material Agreement

$200.0M$5.40$9.0M$9.0M

2.01

Completion of Acquisition or Disposition of Assets** The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by referen

Asset Acquisition

Transaction Details

Acquisition / Disposition

Target: all of the outstanding equity interests in Oratech Pharma, Inc.
Consideration: Lifeward Ordinary Shares, Pre-Funded Warrants, Share Purchase Warrants, and Revenue Sharing Payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products
Structure: Share Purchase Agreement

•Agreement entered January 12, 2026
•Closing occurred March 25, 2026
•Revenue Sharing Payments continue until earliest of: 10 years after closing, receipt of Maximum Amount, or Lifeward market capitalization equals or exceeds $200 million

Material Agreement

Agreement: Share Purchase Agreement
Parties: Oramed Pharmaceuticals Inc., Lifeward Ltd., Oratech Pharma, Inc.

•Lifeward issued 1,250,363 ordinary shares to Oramed
•Lifeward issued 1,006,113 Pre-Funded Warrants at $0.0001 exercise price
•Lifeward issued Share Purchase Warrants for up to 1,296,296 ordinary shares at $5.40 exercise price

Debt / Financing

Instrument: senior secured convertible notes
Principal: 9000000

Exhibits (1)

8-K

CURRENT REPORT